We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AAM Calls for Clarifications in Supply Chain Waiver Guidance
AAM Calls for Clarifications in Supply Chain Waiver Guidance
The Association for Accessible Medicines urged the FDA to clarify its draft guidance on Drug Supply Chain Security Act (DSCSA) waivers by adding an estimated timetable for review decisions.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor